Renal Disease, End Stage
7
0
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Ellipsys Vascular Access System Post Market Surveillance (PS) Study
Improving Medical Decision Making for Older Patients With End Stage Renal Disease
Safety and Efficacy of Apixaban in Severe Renal Impairment
PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment
Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease
Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease
Oral Paricalcitol in Kidney Transplant Recipients